Literature DB >> 2014242

Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.

H G Kräusslich1.   

Abstract

Enzymatically active retroviral proteinases are dimers of identical polypeptide chains with a fold similar to that of other aspartic proteinases. Each polypeptide chain, encoded on one of the viral polyproteins, is less than half the size of cellular aspartic proteinases and contains only one of the two active-site aspartate residues. A plasmid was constructed to generate a genetically linked dimer of the proteinase (PR) of human immunodeficiency virus (HIV) type 1, composed of two copies of the PR sequence linked by a structurally flexible hinge region. The expression product was stable and active against HIV polyprotein substrates. Mutational analysis revealed that the linked dimer, and not multimers thereof, contained the proteolytic activity. Expression of the linked dimer as a component of a HIV polyprotein by in vitro translation gave rapid autocatalytic processing, whereas the wild-type polyprotein was stable on prolonged incubation. Transfection of HIV subviral or proviral constructs, containing the linked dimer of HIV PR, gave premature processing of the viral polyproteins, thus preventing particle formation and infectivity. Premature processing also led to increased cell toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014242      PMCID: PMC51416          DOI: 10.1073/pnas.88.8.3213

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

Review 1.  Viral proteinases.

Authors:  H G Kräusslich; E Wimmer
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

2.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

5.  The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region.

Authors:  M Hadzopoulou-Cladaras; B K Felber; C Cladaras; A Athanassopoulos; A Tse; G N Pavlakis
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

6.  Electrotransfection of human lymphoid and myeloid cell lines.

Authors:  R Döffinger; M Pawlita; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1988-12-23       Impact factor: 16.971

7.  T7 lysozyme inhibits transcription by T7 RNA polymerase.

Authors:  B A Moffatt; F W Studier
Journal:  Cell       Date:  1987-04-24       Impact factor: 41.582

8.  Vectors for selective expression of cloned DNAs by T7 RNA polymerase.

Authors:  A H Rosenberg; B N Lade; D S Chui; S W Lin; J J Dunn; F W Studier
Journal:  Gene       Date:  1987       Impact factor: 3.688

9.  Processing of in vitro-synthesized gag precursor proteins of human immunodeficiency virus (HIV) type 1 by HIV proteinase generated in Escherichia coli.

Authors:  H G Kräusslich; H Schneider; G Zybarth; C A Carter; E Wimmer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

View more
  77 in total

1.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Assembly and processing of human immunodeficiency virus Gag mutants containing a partial replacement of the matrix domain by the viral protease domain.

Authors:  C T Wang; Y C Chou; C C Chiang
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Analysis of human immunodeficiency virus type 1 Gag ubiquitination.

Authors:  Eva Gottwein; Hans-Georg Kräusslich
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers.

Authors:  H Burstein; D Bizub; A M Skalka
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease.

Authors:  Jane M Sayer; Fengling Liu; Rieko Ishima; Irene T Weber; John M Louis
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

Review 7.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

8.  Identifying binding hot spots on protein surfaces by mixed-solvent molecular dynamics: HIV-1 protease as a test case.

Authors:  Peter M U Ung; Phani Ghanakota; Sarah E Graham; Katrina W Lexa; Heather A Carlson
Journal:  Biopolymers       Date:  2016-01       Impact factor: 2.505

9.  An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Authors:  J Konvalinka; M A Litterst; R Welker; H Kottler; F Rippmann; A M Heuser; H G Kräusslich
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation.

Authors:  L M Babé; J Rosé; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.